GOLDMAN SACHS GROUP INC - CATABASIS PHARMACEUTICALS IN ownership

CATABASIS PHARMACEUTICALS IN's ticker is and the CUSIP is 14875P206. A total of 59 filers reported holding CATABASIS PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of CATABASIS PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2021$170,000
+68.3%
80,717
+130.7%
0.00%
Q1 2021$101,000
+197.1%
34,992
+118.7%
0.00%
Q4 2020$34,000
-82.1%
15,998
-47.8%
0.00%
Q3 2020$190,000
-29.6%
30,662
-27.1%
0.00%
Q2 2020$270,00042,0430.00%
Other shareholders
CATABASIS PHARMACEUTICALS IN shareholders Q2 2021
NameSharesValueWeighting ↓
Eversept Partners, LP 522,042$1,117,1700.13%
XTX MARKETS LLC 26,041$56,0000.12%
Samsara BioCapital, LLC 300,000$642,0000.06%
Ikarian Capital, LLC 650,000$1,392,0000.06%
Opaleye Management Inc. 187,750$402,0000.05%
SABBY MANAGEMENT, LLC 108,026$231,0000.04%
Anson Funds Management LP 97,601$209,0000.04%
Virtu Financial LLC 83,221$178,0000.02%
GSA CAPITAL PARTNERS LLP 47,084$101,0000.02%
WEXFORD CAPITAL LP 19,512$42,0000.01%
View complete list of CATABASIS PHARMACEUTICALS IN shareholders